scholarly journals In Vitro Culture and Characterization of Human Lung Cancer Circulating Tumor Cells Isolated by Size Exclusion from an Orthotopic Nude-Mouse Model Expressing Fluorescent Protein

2014 ◽  
Vol 24 (5) ◽  
pp. 1531-1536 ◽  
Author(s):  
Katarina Kolostova ◽  
Yong Zhang ◽  
Robert M. Hoffman ◽  
Vladimir Bobek
2019 ◽  
Vol 12 (4) ◽  
pp. 249-260 ◽  
Author(s):  
Ghulam Jilany Khan ◽  
Li Sun ◽  
Muhammad Abbas ◽  
Muhammad Naveed ◽  
Talha Jamshaid ◽  
...  

Background: Aggressive behavior of tumor metastasis comes from certain mutations, changes in cellular metabolic and signaling pathways that are majorly altered by tumor microenvironment (TME), its other components and growth factors like transforming growth factor-β1 (TGF-β1) which is chiefly known for its epithelial to mesenchymal transformation (EMT). EMT is a critical step of metastasis cascade in actual human lung cancer scenario. Objective: Our present study is focused on unveiling the in-vivo metastatic behavior of TGF-β1 treated lung cancer cells that undergo EMT. Methods: The lung cancer epithelial A549 cells were treated in-vitro with TGF-β1 (3-5ng/ml for 72 h) for EMT. After confirming the transformation of cells by phenotype modifications, wound healing and cell migration assay and qRT-PCR analyses of EMT biomarkers including E. Cadherin, Vimentin, Snail, Slug, MMP2 and MMP9; those TGF-β1 modified cells were probed with fluorescent trackers and were injected into the tail vein of BALB/c nude mice for metastatic dissemination studies. Results: Our findings indicate that the distribution of TGF-β1 treated A549 cells as compared to W.T A549 towards lungs is less in terms of total relative fluorescent cluster count, however, the difference is insignificant (52±4, 60±5 respectively). Additionally, we show that TGF-β1 treated cells tend to metastasize almost 2, 3, 1.5, 2 and 1.7 times more than W.T towards liver, brain, ovaries, bones and adrenal gland, respectively, which is very much like human lung cancer metastasis. Conclusion: Conclusively, it is the first study ever reporting that a pre-treatment of cells with TGF-β1 for experimental lung cancer metastasis mouse model may portray a more precise approach for the development of potential therapeutic treatments. Additional pre-treatment studies with the application of other TME conditions like hypoxia and factors like NFκB, VEGF etc. may be a future prospect to develop a better understanding.


2012 ◽  
Vol 423 (1) ◽  
pp. 158-163 ◽  
Author(s):  
Masafumi Horie ◽  
Akira Saito ◽  
Yu Mikami ◽  
Mitsuhiro Ohshima ◽  
Yasuyuki Morishita ◽  
...  

2021 ◽  
Vol 10 (9) ◽  
pp. 3085-3100
Author(s):  
Kotaro Abe ◽  
Masahiko Kanehira ◽  
Shinya Ohkouchi ◽  
Sakiko Kumata ◽  
Yamato Suzuki ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ronggang Luo ◽  
Yi Zhuo ◽  
Quan Du ◽  
Rendong Xiao

Abstract Background To detect and investigate the expression of POU domain class 2 transcription factor 2 (POU2F2) in human lung cancer tissues, its role in lung cancer progression, and the potential mechanisms. Methods Immunohistochemical (IHC) assays were conducted to assess the expression of POU2F2 in human lung cancer tissues. Immunoblot assays were performed to assess the expression levels of POU2F2 in human lung cancer tissues and cell lines. CCK-8, colony formation, and transwell-migration/invasion assays were conducted to detect the effects of POU2F2 and AGO1 on the proliferaion and motility of A549 and H1299 cells in vitro. CHIP and luciferase assays were performed for the mechanism study. A tumor xenotransplantation model was used to detect the effects of POU2F2 on tumor growth in vivo. Results We found POU2F2 was highly expressed in human lung cancer tissues and cell lines, and associated with the lung cancer patients’ prognosis and clinical features. POU2F2 promoted the proliferation, and motility of lung cancer cells via targeting AGO1 in vitro. Additionally, POU2F2 promoted tumor growth of lung cancer cells via AGO1 in vivo. Conclusion We found POU2F2 was highly expressed in lung cancer cells and confirmed the involvement of POU2F2 in lung cancer progression, and thought POU2F2 could act as a potential therapeutic target for lung cancer.


1996 ◽  
Vol 14 (4) ◽  
pp. 351-357 ◽  
Author(s):  
Xin-Hai Pei ◽  
Yoichi Nakanishi ◽  
Koichi Takayama ◽  
Jun Yatsunami ◽  
Feng Bai ◽  
...  

Oncogene ◽  
2003 ◽  
Vol 22 (12) ◽  
pp. 1892-1905 ◽  
Author(s):  
Hiroyuki Konishi ◽  
Miyabi Sugiyama ◽  
Kotaro Mizuno ◽  
Hiroko Saito ◽  
Yasushi Yatabe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document